Advanced Medical Solutions Group (AMS) H1 2026 TU earnings summary

Executive summary

• Half year 2026 revenues expected at approximately £115.2 million, up from £110.8 million in H1 2025, despite some order delays and de-stocking in Europe.

• Strategic focus on expanding direct sales in Europe impacted sales due to de-stocking, but integration of Peters Surgical and Syntacoll is progressing as planned.

• Leadership expresses confidence in future prospects and sustained long-term value creation.

Financial highlights

• Revenue for H1 2026 is expected to increase by about 4% year-over-year compared to H1 2025.

• Some first half orders shipped later than planned, affecting reported period sales.

Outlook and guidance

• Full year 2026 EBITDA is expected to be in line with current market expectations.

• Clear top-line growth trajectory anticipated, with margin improvement and scalable growth.